An antibody-drug conjugate drug for breast cancer, jointly developed by AstraZeneca Plc and Daiichi Sankyo Co Ltd, failed to show statistical significance in overall survival at Phase 3 versus chemotherapy despite having achieved progression free survival for the same patient group. Announcing the results on 23 September, AstraZeneca said that the survival results were likely to have been affected by changes in the standard of care for breast cancer during the drug’s development period.
